In breast cancer patients, the impact of TAGLN2 may operate via activation of the NRP1/VEGFR2 and MAPK pathways, as in gastric cancer, promoting angiogenesis and cell survival [119]; the Rap1/PI3K/AKT pathway, as reported in papillary thyroid cancer, to enhance invasion [117]; or, akin to colorectal cancer progression, by activating STAT3 and regulating ANXA2 [118]. This evidence concerns the gene AKT1 and breast cancer.